ArticleArchiv der Pharmazie2026
Olikomycin A Disrupts Gram-Positive Bacterial Membranes Through Calcium-Dependent Binding to Phosphatidylglycerol.
Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Calcium-dependent antibiotics (CDAs) represent an important class of antimicrobial agents active against Gram-positive pathogens. Olikomycin A, produced by Streptomyces ghanaensis ΔwblA, displays potent activity against multidrug-resistant bacteria; however, its molecular mode of action remained unclear. In this study, we investigated the interaction of olikomycin A with bacterial membrane lipids. Phospholipid antagonization assays demonstrated a calcium-dependent interaction with phosphatidylglycerol (PG), a major anionic phospholipid of Gram-positive membranes. Cryo-electron microscopy and fluorescence microscopy using model membranes revealed rapid membrane disruption induced by olikomycin A, resulting in vesicle deformation and fragmentation. Compared with the clinically used lipopeptide daptomycin, olikomycin A caused markedly faster and more extensive membrane damage. Furthermore, treatment of Staphylococcus aureus with olikomycin A in the presence of calcium resulted in rapid cellular aggregation consistent with severe membrane perturbation. These findings indicate that olikomycin A targets bacterial membranes via calcium-dependent binding to PG and disrupts membrane integrity through a mechanism distinct from daptomycin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.